• February 25, 2019
• 0

Novartis has acquired rights to TQJ230 from Akcea Therapeutics, a novel cardiovascular drug that could become first-in-class and has the potential to treat million of patients. TQJ230 is based on the...

• January 9, 2019
• 0

The National Institute for Health Care and Excellent (NICE) has rejected Novartis' migraine drug Aimovig (erenumab) as preventative treatment for migraine in draft guidelines. The news comes after Aimovig was...